Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Daxokafusp Alfa · SAR-445877

Fusion protein · Immune activation, directed at programmed cell death protein 1 (PDCD1) and interleukin-15 receptor (IL15RA) · developed by Sanofi

Phase 2 Most advanced trial
SNY Developer
1 Registered trials

What is Daxokafusp Alfa?

Daxokafusp alfa is a fusion protein with an antibody moiety that binds PD-1 and blocks its inhibitory signaling, linked to a mutein of the cytokine IL-15 that activates IL-15 receptor signaling. It is being studied in non-small cell lung cancer refractory to immune checkpoint inhibitors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
SAR-445877
Drug type
Fusion protein
Targets
programmed cell death protein 1 (PDCD1), interleukin-15 receptor (IL15RA)
Mechanism
Immune activation, directed at programmed cell death protein 1 (PDCD1) and interleukin-15 receptor (IL15RA)
Pathways
PD-1 signaling, IL-15 signaling, NK cell proliferation, CD8+ T cell activation
Therapy area
Oncology
Developer
Sanofi (SNY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
4T4NBT8HHY

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07133425 Phase 2 Non-Small Cell Lung Cancer Recruiting SNY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

ICI-refractoryNon-Small Cell Lung Cancer

Other drugs acting on PDCD1 / IL15RA

More from Sanofi

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the SNY page.

Follow SNY, the company behind Daxokafusp Alfa

See SNY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SNY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.